Page 6 - Pharma Stocks

Price drives growth of Rs 1.4 trillion pharma market, hits a five-year high

The rapid growth of the trade generics market which accounts for a third of pharma volumes is another trend which is impacting volume as well as overall growth of the branded segment

Pharma index set to post its biggest monthly gain in 21 years amid Covid-19

Analysts, however, do caution against the rich valuation the pharma index and the stocks are trading at

Investors should stick to stocks of firms focused on domestic market

Pharma firms can build brands and enjoy higher margins here

Cipla, Biocon, Divi's Lab: Pharma stocks to bet on in the current market

Cipla may see profit-booking around Rs 360 to Rs 367 levels, as per the weekly chart.

Growth in domestic market likely to provide booster dose for pharma stocks

The pharma sector, once considered a safe bet, has been trailing the benchmark indices for four years in a row

Pharma stocks advance; Ipca Labs, Cadila Healthcare soar up to 19%

Given India is relatively better placed to scale up and due to lower outbreak of Covid-19, India may benefit by supplying more to US and EU, analysts say.

Market Wrap, Feb 25: Sensex slips 82 pts, Nifty gives up 11,800

On the sectoral front, Nifty Pharma index dropped over 2 per cent to end as the biggest sectoral index loser. The index closed at 7,937 levels

FIIs rejig sectoral exposure ahead of Budget; pick pharma stocks, drop IT

Investors bet in anticipation of easing of regulatory issues in the pharma segment

Pharma stocks gain; Divi's Labs, Dr Reddy's, Pirmal Enterprises rise 1.50%

Indian pharma market (IPM) registered a 14.5 per cent year-on-year (YoY) growth in November, one of the best growths seen in more than 32 months.

Dr Reddy's Labs shines among pharma stocks, wins investor confidence

The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year

From Dr Reddy's to Cipla, pharma companies aren't out of the woods: Experts

The Street is cautious given multiple challenges in core markets of US and India

Pharma funds remain in poor health amid headwinds on compliance

The BSE Healthcare Index has fallen 10 per cent in the last one year

Lupin, Divi's Lab, Aurobindo Pharma: Here's how you can trade pharma stocks

A major bullish trend may start only above the range of 8,600 - 8,500 level, that said it seems far considering the resistance of 8,400 level.

Pharma sector likely to bounce back in 2019 after three years of slump

Stability in pricing for the second consecutive quarter may bring back buoyancy

From Sun Pharma to Lupin, pharma stocks rally on quarterly show

Companies put up stellar performance in Indian as well as US markets

Re-rating likely of pharma stocks

The BSE Healthcare index has been one of the biggest gainers over the past few days, on easing of regulatory concerns, improving visibility over product launches and a return of growth in the domestic market.Ranjit Kapadia of Centrum Broking believes there are encouraging signs which could lead to a re-rating of pharmaceutical stocks, on the back of re-stocking in India and some recovery in the American market. Earlier, most analysts had thought there would be no revenue growth in the US market for large generic players for at least a year. The expected recovery there, led by niche product launches and regulatory clearances for affected plants, could now start in the March quarter of FY18, instead of FY19. Barring Cipla, the top five Indian pharma companies by market capitalisation get upwards of 40 per cent of their revenue from the US market. The key trigger for the segment has been the recent regulatory clearances for factories here, earlier pulled up for not meeting the US Food ..

Pharma stocks on mutual funds' radar post price correction

Domestic mutual funds (MFs) have taken a liking to pharmaceutical stocks, following a steep fall in the latter's prices.While they expect the pharma sector to undergo headwinds, they are taking a contrarian view on select stocks, with an investment horizon of two to three years. Sun Pharmaceutical, Apollo Hospital Enterprise, Dr Reddy's Laboratories, Aurobindo Pharma and Fortis Healthcare were among the most-bought stocks in the month of May by fund managers. Last month, Divi's Laboratories, along with Aurobindo and Fortis Healthcare, were the top picks.S Naren, chief investment officer (CIO) at ICICI Prudential MF, says, "India's pharmaceutical companies have been under intense scrutiny from the US Food and Drug Administration (FDA) over the past few years. This has led to considerable price erosion. With popularity of this sector at a multi-year low, the ownership of stocks in the sector saw a steep decline. We believe, at the current juncture, the (share of the) sector is largely ..

Fund managers make contrarian bets on pharma stocks

Sun Pharma emerged as top choice since equity mutual funds added about 15 mn shares to portfolio

Pharma stocks decline on fears of new US order, competition

Pharmaceutical sector stocks slipped on Friday, following adverse observations from the US regulator, the Food and Drug Administration (FDA), increased competition and fears of a new pricing policy in the US.The BSE healthcare index declined 1.5 per cent on Friday. On a year to date basis, it (comprising 69 companies) is down nearly four per cent, while the overall benchmark has risen 16-17 per cent.IPCA Laboratories was the biggest loser, with the US having banned drug import from its three plants. The stock fell a little over 15 per cent in intra-day trade but recovered to close eight per cent lower at Rs 471.70. Its plants in Madhya Pradesh and Silvassa were under a US import alert since 2014 and 2015, respectively; the company was exporting limited products, exempted from the ban. On Thursday, the company said the FDA had withdrawn those exemptions.Lupin's stock fell 4.4 per cent, after Aurobindo Pharma received approval for the first generic version of Renvela, used for ...

Despite fall, muted FY18 outlook will keep pharma stocks under pressure

Company expects a single-digit decline in FY18 revenues, which took Street by surprise